ASH 2023: ELEVATE-TN Study – 6-Year Follow-up of Acalabrutinib Efficacy in CLL
The ELEVATE-TN study offers compelling long-term data on acalabrutinib’s effectiveness in treating chronic lymphocytic leukemia, showcasing sustained benefits and safety over 74.5 months.